Hypothyroidism Market Research Report – Global Forecast till 2027

Hypothyroidism Market Research Report: by Type of Hypothyroidism (Primary, Secondary, Tertiary Hypothyroidism), by Diagnosis & Treatment (Diagnosis, Treatment (Levothyroxine, others)), by Route of Administration (Oral, Intravenous), End User - Global Forecast Till 2027

ID: MRFR/Pharma/5493-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data

Market Scenario:


Global Hypothyroidism Market is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 3.7% over the forecast period. -Hypothyroidism is a condition in which the thyroid is underactive or non-active. The most common symptoms of hypothyroidism are weight gain, water retention, constipation, fatigue, daytime sleepiness, and others.


Rising prevalence of hypothyroidism is one of the key factors driving the Hypothyroidism Market. According to a recent article published by the American Thyroid Association, more than 12% of the US population develops a thyroid disorder during their lifetime and similar trend has been observed in different geographies such as UK, India, and others.


Various other factors such as rising awareness about hypothyroidism, developing healthcare infrastructure, increasing research & development activities related to healthcare and favourable reimbursement and funding policies are also expected to propel the growth of the market.


However, the side-effects related to available therapeutics can hamper the market growth over the forecast period. Some of the hypothyroidism drugs in the market such as Synthroid, euthyrox, and others show mild side-effects ranging from fever, headache, insomnia, etc. to tremors, and others. Thus, it is projected that side-effects related to the use of drugs are likely to restrict the market growth.


Segmentation:


The Global Hypothyroidism Market has been segmented into type of hypothyroidism, diagnosis & treatment, route of administration, and end user.The market, on the basis of type of hypothyroidism, has been segmented into primary hypothyroidism, secondary hypothyroidism, and tertiary hypothyroidism.The market, by diagnosis & treatment, has been segmented into diagnosis and treatment. The diagnosis segment is further classified as physical examination, blood tests, imaging scan, and others. The treatment segment is further classified as levothyroxine sodium, liothyronine, and natural desiccated thyroid (NDT).


 The market, by route of administration, has been segmented into oral, intravenous, and others.The market, by end user, has been segmented into hospitals, clinics, research & academic institutes, and others. The hospitals segment is anticipated to hold the largest market share owing to the increasing cases of hypothyroidism. The research & academic institutes are expected to grow at the highest CAGR owing to the ongoing research on better treatment approaches.The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Hypothyroidism Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European Hypothyroidism Market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The Hypothyroidism Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Hypothyroidism Market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players:


Pfizer Inc., AbbVie Inc., Merck & Co., Inc., ALLERGAN, Mylan N.V., Erfa Canada Inc, Novartis AG, GlaxoSmithKline plc, RLC Labs and others are some of the key players in the Global Hypothyroidism Market.


Regional Market Summary


Global Hypothyroidism Market Share (%), by Region, 2017


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports


Geographically, the Americas is anticipated to dominate the global hypothyroidism market owing to rising healthcare expenditure, increasing cases of hypothyroidism and rising awareness of hypothyroidism. The American Association of Clinical Endocrinologists (AACE) introduced the blue paisley ribbon as a symbol for thyroid awareness in 2012. This was aimed to create awareness for thyroid disorders (considering the example of preliminary pink ribbon symbol for breast cancer). Following the same course, the organization later in 2013, offered a variety of free promotional items for the awareness of thyroid in public interest.


Europe is expected to hold the second largest position in the global hypothyroidism market. The market growth in this region is attributed to the government support and improving healthcare related research & development activities.


The hypothyroidism market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing demand for minimally invasive surgeries and rising healthcare spending. According to the World Bank Group, India spent 3.89% of its Gross Domestic Product (GDP) on health.


The Middle East & Africa are expected to hold the least share of the market. The market growth in this region is expected to be driven by a developing healthcare infrastructure.


Global Hypothyroidism Market, by Type of Hypothyroidism:



  •       Primary Hypothyroidism

  •       Secondary Hypothyroidism

  •       Tertiary Hypothyroidism


Global Hypothyroidism Market, by Diagnosis & Treatment:



  • Diagnosis

    • Physical Examination

    • Blood tests

    • Imaging Scan

    • Others



  • Treatment

    • Levothyroxine Sodium

    • Liothyronine

    • Natural Desiccated Thyroid (NDT)




Global Hypothyroidism Market, by Route of Administration:



  •       Oral

  •        Intravenous

  •        Others


Global Hypothyroidism Market, by End User:



  •       Hospitals

  •       Clinics

  •        Research & Academic Institutes

  •        Others


Global Hypothyroidism Market, by Region:



  • Americas

    • North America

      • US

      • Canada



    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • The Middle East & Africa

    • Middle East

    • Africa




Global Hypothyroidism Market, by Key Players:



  •        Medtronic

  •        Pfizer Inc.

  •        AbbVie Inc.

  •        Merck & Co., Inc.

  •        ALLERGAN

  •        Mylan N.V.

  •        Erfa Canada Inc

  •        Novartis AG

  •        GlaxoSmithKline plc

  •        RLC Labs


Intended Audience:



  • Pharmaceutical Companies

  • Research and Development Organization

  • Drug Manufacturers

  • Healthcare Organizations

  • Academics and Research Institutes


 


 


 


 



Frequently Asked Questions (FAQ) :


Hypothyroidism market projected to grow at a 3.7% CAGR between 2018-2023.

Developing healthcare infrastructure and favorable reimbursement are the key factors driving the hypothyroidism market.

Mild side effects may limit the hypothyroidism market growth.

Key players profiled in the hypothyroidism market include RLC Labs, GlaxoSmithKline plc, Novartis AG, Erfa Canada Inc, Mylan N.V., ALLERGAN, Merck & Co., Inc., AbbVie Inc., and Pfizer Inc.

Specific strategies that industry players have incorporated to create a niche in the hypothyroidism market include extensive R&D, collaborations, mergers, and product launches.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Product Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Hypothyroidism Market, by Type of Hypothyroidism

6.1 Introduction

6.2 Primary Hypothyroidism

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Secondary Hypothyroidism

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Tertiary Hypothyroidism

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Hypothyroidism Market, by Diagnosis & Treatment

7.1 Introduction

7.2 Diagnosis

7.2.1 Physical Examination

Market Estimates & Forecast, by Region, 2020–2027

7.2.2 Blood Tests

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.3 Imaging Scan

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.4 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Treatment

7.3.1 Levothyroxine Sodium

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.2 Liothyronine

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.3 Natural Desiccated Thyroid (NDT)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Hypothyroidism Market, by Route of Administration

8.1 Introduction

8.2 Oral

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Intravenous

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Hypothyroidism Market, by End User

9.1 Introduction

9.2 Hospitals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.3 Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.4 Research & Academic Institutes

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.5 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 10. Global Hypothyroidism Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 PFIZER INC.

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 AbbVie Inc.

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 MERCK & CO., INC.

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 ALLERGAN

12.4.1 Company Overview

12.4.2 Product Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Mylan N.V.

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Erfa Canada Inc

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Novartis AG

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 GlaxoSmithKline plc

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 RLC Labs

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Cannula Industry

Chapter 14. Appendix

LIST OF TABLES

Table 1 Global Hypothyroidism Market Synopsis, 2020–2027

Table 2 Global Hypothyroidism Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Hypothyroidism Market, by Region, 2020–2027 (USD Million)

Table 4 Global Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)

Table 5 Global Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)

Table 6 Global Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)

Table 7 Global Hypothyroidism Market, by End User, 2020–2027 (USD Million)

Table 8 North America: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)

Table 9 North America: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)

Table 10 North America: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)

Table 11 North America: Hypothyroidism Market, by End User, 2020–2027 (USD Million)

Table 12 US: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)

Table 13 US: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)

Table 14 US: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)

Table 15 US: Hypothyroidism Market, by End User, 2020–2027 (USD Million)

Table 16 Canada: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)

Table 17 Canada: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)

Table 18 Canada: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)

Table 19 Canada: Hypothyroidism Market, by End User, 2020–2027 (USD Million)

Table 20 South America: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)

Table 21 South America: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)

Table 22 South America: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)

Table 23 South America: Hypothyroidism Market, by End User, 2020–2027 (USD Million)

Table 24 Europe: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)

Table 25 Europe: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)

Table 26 Europe: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)

Table 27 Europe: Hypothyroidism Market, by End User, 2020–2027 (USD Million)

Table 28 Western Europe: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)

Table 29 Western Europe: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)

Table 30 Western Europe: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)

Table 31 Western Europe: Hypothyroidism Market, by End User, 2020–2027 (USD Million)

Table 32 Eastern Europe: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)

Table 33 Eastern Europe: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)

Table 34 Eastern Europe: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)

Table 35 Eastern Europe: Hypothyroidism Market, by End User, 2020–2027 (USD Million)

Table 36 Asia-Pacific: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)

Table 37 Asia-Pacific: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)

Table 38 Asia-Pacific: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)

Table 39 Asia-Pacific: Hypothyroidism Market, by End User, 2020–2027 (USD Million)

Table 40 Middle East & Africa: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)

Table 41 Middle East & Africa: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)

Table 42 Middle East & Africa: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)

Table 43 Middle East & Africa: Hypothyroidism Market, by End User, 2020–2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Market Structure for Global Hypothyroidism Market

Figure 3 Market Dynamics for Global Hypothyroidism Market

Figure 4 Global Hypothyroidism Market Share, by Type of Hypothyroidism, 2020

Figure 5 Global Hypothyroidism Market Share, by Diagnosis & Treatment, 2020

Figure 6 Global Hypothyroidism Market Share, by Route of Administration, 2020

Figure 7 Global Hypothyroidism Market Share, by End User, 2020

Figure 8 Global Hypothyroidism Market Share, by Region, 2020

Figure 9 North America: Hypothyroidism Market Share, by Country, 2020

Figure 10 Europe: Hypothyroidism Market Share, by Country, 2020

Figure 11 Asia-Pacific: Hypothyroidism Market Share, by Country, 2020

Figure 12 Middle East & Africa: Hypothyroidism Market Share, by Country, 2020

Figure 13 Global Hypothyroidism Market: Company Share Analysis, 2020 (%)

Figure 14 PFIZER INC.: Key Financials

Figure 15 PFIZER INC.: Segmental Revenue

Figure 16 PFIZER INC.: Geographical Revenue

Figure 17 AbbVie Inc.: Key Financials

Figure 18 AbbVie Inc.: Segmental Revenue

Figure 19 AbbVie Inc.: Geographical Revenue

Figure 20 MERCK & CO., INC.: Key Financials

Figure 21 MERCK & CO., INC.: Segmental Revenue

Figure 22 MERCK & CO., INC.: Geographical Revenue

Figure 23 ALLERGAN: Key Financials

Figure 24 ALLERGAN: Segmental Revenue

Figure 25 ALLERGAN: Geographical Revenue

Figure 26 Mylan N.V.: Key Financials

Figure 27 Mylan N.V.: Segmental Revenue

Figure 28 Mylan N.V.: Geographical Revenue

Figure 29 Erfa Canada Inc: Key Financials

Figure 30 Erfa Canada Inc: Segmental Revenue

Figure 31 Erfa Canada Inc: Geographical Revenue

Figure 32 Novartis AG: Key Financials

Figure 33 Novartis AG: Segmental Revenue

Figure 34 Novartis AG: Geographical Revenue

Figure 35 GlaxoSmithKline plc: Key Financials

Figure 36 GlaxoSmithKline plc: Segmental Revenue

Figure 37 GlaxoSmithKline plc: Geographical Revenue

Figure 38 RLC Labs: Key Financials

Figure 39 RLC Labs: Segmental Revenue

Figure 40 RLC Labs: Geographical Revenue

Figure 41 McKesson Medical-Surgical Inc.: Key Financials

Figure 42 McKesson Medical-Surgical Inc.: Segmental Revenue

Figure 43 McKesson Medical-Surgical Inc.: Geographical Revenue

Figure 44 Harsoria Healthcare Pvt. Ltd.: Key Financials

Figure 45 Harsoria Healthcare Pvt. Ltd.: Segmental Revenue

Figure 46 Harsoria Healthcare Pvt. Ltd.: Geographical Revenue

Figure 47 ISPG Inc.: Key Financials

Figure 48 ISPG Inc.: Segmental Revenue

Figure 49 ISPG Inc.: Geographical Revenue

Figure 50 ILIFE MEDICAL DEVICES PRIVATE LIMITED (INDIA): Key Financials

Figure 51 ILIFE MEDICAL DEVICES PRIVATE LIMITED (INDIA): Segmental Revenue

Figure 52 ILIFE MEDICAL DEVICES PRIVATE LIMITED (INDIA): Geographical Revenue

Figure 53 Denex International: Key Financials

Figure 54 Denex International: Segmental Revenue

Figure 55 Denex International: Geographical Revenue

Figure 56 BD: Key Financials

Figure 57 BD: Segmental Revenue

Figure 58 BD: Geographical Revenue